Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

Inclusion Criteria:

• Subject has a documented history of UC and is either in remission or currentlypresents with mildly to moderately active UC symptoms as determined by theinvestigator upon subject interview of UC symptoms, (e.g., urgency, bowel frequency,and rectal bleeding). Additionally, the diagnosis of UC must be confirmed by pastflexible sigmoidoscopy/colonoscopy which may include colonic mucosal pathologicalfindings on biopsy consistent with UC.

• Subject is capable and willing to comply with all study procedures.

Exclusion Criteria:

• Subject has a history of allergy or intolerance to aspirin, mesalamine or othersalicylates.

• Subject has participated in an investigational drug or device study, other than aprevious balsalazide disodium tablet trial (i.e., BZUC3002 or BZUC3003), within 30days of entering the current study.

• Subject discontinued from a previous balsalazide disodium tablet study due to studydrug-related AE(s), including UC flare or associated symptoms that were perceived bythe subject/investigator as being caused by study drug.

• Subject has had any prior bowel surgery, except appendectomy and cholecystectomy.

• Subject has unstable cardiovascular, coagulopathy, or pulmonary disease.

• Regular use of nonsteroidal anti-inflammatory drugs (NSAIDS) except cardioprotectiveASA (i.e., less than or equal to 162 mg ASA per day).

• Subject has a history of human immunodeficiency virus (HIV) or hepatitis (B and C).Subjects with a history of hepatitis B and C will be eligible provided the screeningLFTs are within normal limits.